Navigation Links
Quest Diagnostics Commences Tender Offer for Acquisition of Celera
Date:3/28/2011

MADISON, N.J., March 28, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today it has commenced a tender offer through its wholly owned subsidiary, Spark Acquisition Corporation, for all of the outstanding shares of common stock (the "Shares") of Celera Corporation (Nasdaq: CRA), one of the world's pioneers in genetic diagnostics discovery and development for $8.00 per share in cash, without interest and less any required withholding taxes.

The tender offer is being made pursuant to an Offer to Purchase, dated March 28, 2011, and in connection with the previously announced Agreement and Plan of Merger, dated March 17, 2011, by and among Quest Diagnostics, Spark Acquisition Corporation and Celera.

The tender offer will expire on April 25, 2011, at 5:00 p.m. New York City time, unless extended in accordance with the Merger Agreement and the applicable rules and regulations of the Securities and Exchange Commission.  Any extension of the tender offer will be followed as promptly as practicable by public announcement thereof, and such announcement will be made no later than 9:00 a.m. New York City time on the next business day after the previously scheduled expiration date.

The tender offer is subject to customary conditions, including the tender of a majority of the outstanding Shares (calculated on a fully-diluted basis), as well as the receipt of certain regulatory approvals and other closing conditions.  The board of directors of each of Quest Diagnostics and Celera have approved the transaction.

Today, Quest Diagnostics will file with the SEC a tender offer statement on Schedule TO, setting forth in detail the terms of the tender offer.  Celera will file today with the SEC a solicitation/recommendation statement on Schedule 14D-9 setting forth in detail, among other things, the recommendation of Celera's board of directors that Celera stockholders accept the tender offer and tender their Shares pursuant to the offer.

The Depositary for the tender offer is Computershare Trust Company, N.A.  The Information Agent for the tender offer is D.F. King & Co., Inc.  The Dealer Manager for the tender offer is Morgan Stanley & Co. Incorporated.  The tender offer materials may be obtained at no charge by downloading them from the SEC's website at http://www.sec.gov.  In addition, a copy of the offer to purchase, letter of transmittal and certain related tender offer documents may be obtained free of charge by directing a request to Quest Diagnostics at 973-520-2900.  A copy of the tender offer statement and Celera's solicitation/recommendation statement on Schedule 14D-9 will be made available to all stockholders of Celera free of charge at http://www.celera.com.

ABOUT QUEST DIAGNOSTICS:Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions.  Quest Diagnostics offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.  Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. More information is available at: http://www.QuestDiagnostics.com.

LEGAL NOTICES AND DISCLAIMERS:This release is for informational purposes only.  It does not constitute an offer to purchase shares of Celera or a solicitation/recommendation under the rules and regulations of the SEC.  Quest Diagnostics is filing with the SEC a Tender Offer Statement on Schedule TO and Celera is filing a Solicitation/Recommendation Statement on Schedule 14D-9.  These documents contain important information and shareholders of Celera are advised to carefully read these documents before making any decision with respect to the cash tender offer.  These documents will be available at no charge on the SEC's website at http://www.sec.gov.  In addition, a copy of the offer to purchase, letter of transmittal and certain related tender offer documents may be obtained free of charge by directing a request to Quest Diagnostics at 973-520-2900.  A copy of the tender offer statement and Celera's solicitation/recommendation statement on Schedule 14D-9 will be made available to all stockholders of Celera free of charge at http://www.celera.com. CONTACTS:Investor related questions, via the Information Agent for the tender offer:D.F. King & Co., Inc.

Banks and Brokers:  212-269-5550Stockholders and All Others:  1-800-347-4250For Quest Diagnostics: Kathleen Valentine (Investors), +1-973-520-2900, or Wendy Bost (Media), +1-973-520-2800
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SimQuest Develops Worlds First Platform for Open Surgical Simulation
2. Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR
3. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
4. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
5. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
6. CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
7. Questcor Pharmaceuticals Selects BDO USA as its Auditor
8. Questcor Reports 2010 Financial Results
9. Physicians Who Treat Obesity Question FDA Rejection of Contrave
10. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
11. Quest Diagnostics Announces Pricing in Offering of Common Stock by the Companys Largest Shareholder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Despite last week’s ... expect Janet Yellen and company to wait until March 2017 for an interest rate ... J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its ... partner for the Tamika Catchings Legacy Tour that will commemorate the Indiana ... hardwood basketball surfaces in all forms and levels of the game, Connor Sports has ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is a common ... long-term patient survival, reports a team of UPMC researchers in the largest study ... Journal of Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead ...
Breaking Medicine News(10 mins):